Cart
sales@molnova.com
GP 1a
CAS No. 511532-96-0
GP 1a( —— )
Catalog No. M35265 CAS No. 511532-96-0
GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 107 | In Stock |
|
| 10MG | 169 | In Stock |
|
| 25MG | 341 | In Stock |
|
| 50MG | 496 | In Stock |
|
| 100MG | 706 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1423 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGP 1a
-
NoteResearch use only, not for human use.
-
Brief DescriptionGP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays.
-
DescriptionGP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor | PERK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number511532-96-0
-
Formula Weight441.35
-
Molecular FormulaC23H22Cl2N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (283.22 mM; Ultrasonic )
-
SMILESC(NN1CCCCC1)(=O)C=2C3=C(N(N2)C4=C(Cl)C=C(Cl)C=C4)C=5C(C3)=CC(C)=CC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhao C, et al. An enzyme-responsive Gp1a-hydrogel for skin wound healing. J Biomater Appl. 2021;36(4):714-721.?
molnova catalog
related products
-
Hemopressin (rat)
Bioactive endogenous peptide substrate for endopeptidase 24.15 (ep24.15), neurolysin (ep24.16) and ACE. Ki values are 27.76, 3.43 and 1.87 μM respectively. Potent hypotensive in vivo. Also acts as a selective CB1 receptor inverse agonist. Displays antinociceptive activity and induces hypophagia in vivo.
-
VCE-004.3
VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator.
-
EHP-101
VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.
